Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Receives Average Rating of “Buy” from Brokerages

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) has received an average rating of “Buy” from the five analysts that are currently covering the company, MarketBeat reports. Five analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $36.60.

A number of equities analysts recently commented on the company. Evercore ISI increased their price target on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. JPMorgan Chase & Co. raised their target price on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Finally, Jefferies Financial Group initiated coverage on shares of Kiniksa Pharmaceuticals in a research note on Friday, September 13th. They set a “buy” rating and a $40.00 price target on the stock.

Kiniksa Pharmaceuticals Trading Up 1.1 %

Shares of KNSA opened at $22.04 on Wednesday. The business’s 50 day moving average is $24.23 and its 200 day moving average is $22.91. Kiniksa Pharmaceuticals has a 12-month low of $15.52 and a 12-month high of $28.15. The company has a market capitalization of $1.59 billion, a PE ratio of -157.42 and a beta of 0.35.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, October 29th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.17). The company had revenue of $112.21 million during the quarter, compared to analysts’ expectations of $111.51 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The firm’s revenue for the quarter was up 67.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.20) EPS. Equities research analysts predict that Kiniksa Pharmaceuticals will post -0.55 earnings per share for the current year.

Insider Activity

In related news, COO Eben Tessari sold 17,000 shares of the stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $26.87, for a total value of $456,790.00. Following the sale, the chief operating officer now directly owns 109,975 shares of the company’s stock, valued at $2,955,028.25. This represents a 13.39 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider John F. Paolini sold 60,692 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $26.12, for a total value of $1,585,275.04. Following the completion of the sale, the insider now owns 52,038 shares in the company, valued at approximately $1,359,232.56. The trade was a 53.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 95,192 shares of company stock valued at $2,479,390. 54.57% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. XTX Topco Ltd grew its position in shares of Kiniksa Pharmaceuticals by 62.2% during the 3rd quarter. XTX Topco Ltd now owns 27,302 shares of the company’s stock worth $682,000 after buying an additional 10,474 shares in the last quarter. Castleark Management LLC bought a new position in Kiniksa Pharmaceuticals in the third quarter worth approximately $4,178,000. Jane Street Group LLC lifted its holdings in Kiniksa Pharmaceuticals by 1,064.4% during the third quarter. Jane Street Group LLC now owns 345,092 shares of the company’s stock worth $8,624,000 after buying an additional 315,456 shares during the period. Wellington Management Group LLP bought a new stake in Kiniksa Pharmaceuticals during the 3rd quarter valued at $1,192,000. Finally, Quarry LP purchased a new position in shares of Kiniksa Pharmaceuticals in the 3rd quarter valued at $50,000. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.